H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on TrovaGene (NASDAQ: TROV) today and set a price target of $2.50. The company’s shares closed yesterday at $0.82, close to its 52-week low of $0.79.
According to TipRanks.com, Selvaraju is a 2-star analyst with an average return of 0.3% and a 39.8% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as IntelliPharmaCeutics International, Biospecifics Technologies Corp, and EyePoint Pharmaceuticals Inc.
Currently, the analyst consensus on TrovaGene is Moderate Buy and the average price target is $2.75, representing a 235.8% upside.
In a report issued on June 15, Maxim Group also upgraded the stock to Buy with a $3 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $19.56 and a one-year low of $0.79. Currently, TrovaGene has an average volume of 1.21M.
Based on the recent corporate insider activity of 22 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of TROV in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Trovagene, Inc. is a clinical-stage, precision medicine oncology therapeutics company. Its focuses on developing PCM-075, is a Polo-like Kinase 1 (PLK1) selective adenosine triphosphate (ATP) competitive inhibitor.
Read More on TROV:
